Active product line.
Ceretropic Labs product reaches researchers through regional distribution partners. For purchase inquiries, use the partner listed under each product.
GHK-Cu Official
Copper tripeptide research formulation. 50mg lyophilized vial in phosphate-buffered reconstitution solution with phenol preservative and polysorbate stabilizer.
Specifications
| Compound | GHK-Cu (Glycyl-Histidyl-Lysine + Cu2+) |
| CAS | 89030-95-5 |
| Molecular formula | C14H22CuN6O4 |
| Molecular weight | 402.84 g/mol |
| Vial contents | 50 mg lyophilized powder |
| Purity | ≥ 99% (HPLC) |
| Appearance | Blue crystalline powder (copper complex) |
| Recommended solvent | Ceretropic Labs reconstitution solution (included) |
| Post-reconstitution stability | Up to 42 days refrigerated (2-8°C) |
| Storage (unopened) | Room temperature acceptable up to 30 days; refrigerated for long-term |
| Lot traceability | Batch number on every vial links to HPLC chromatogram |
Why the formulation differs
Most grey market GHK-Cu ships as powder with bacteriostatic water recommended for reconstitution. That works short-term but creates problems: copper catalyzes slow oxidation of the peptide in neutral pH water, aggregation at the air-liquid interface after repeated vial punctures, and shorter usable post-reconstitution window.
Our formulation uses phosphate buffer at pH 6.5 to hold the peptide at its stability sweet spot, polysorbate 80 to prevent interface aggregation across daily use, and phenol as a preservative with stronger antimicrobial profile than benzyl alcohol. The same approach is used in branded pharmaceutical peptide pens for the same reasons.
Distribution
GHK-Cu Official is distributed in the Serbian market by ghkcu.rs.
Pipeline products
The following compounds are in formulation and QC work. Launch dates are targets, not commitments. Each one goes through the same batch-verification protocol before release.
Retatrutide
Triple agonist GLP-1/GIP/glucagon compound. 10mg vial with proprietary buffered formulation for extended stability.
Tirzepatide
Dual GIP/GLP-1 agonist. 10mg vial with the same buffered formulation platform as the GHK-Cu Official launch.
BPC-157
Pentadecapeptide gastric compound. 5mg vial with phosphate-buffered reconstitution system.
TB-500
Thymosin Beta-4 full peptide. 10mg vial. Paired with BPC-157 for research applications requiring the classic tissue-repair combination.
MOTS-c
Mitochondrial-derived peptide. 10mg vial. Pipeline product for metabolic research applications.
Epithalon
Tetrapeptide from Khavinson research. 20mg vial for extended-cycle research protocols.